Movement Alert｜Abivax S.A. Falls 5.85% in Pre-Market Trading, H1 miss and target-price cuts remain an overhang

Market Focus10-19

On October 19, Abivax S.A. fell 5.85% in Pre-Market Trading, trading at $82.58 with turnover of $1.3554 million.

The move aligns with continuing pressure from the company’s H1 results and subsequent analyst target-price cuts, which remained the most recent clear catalyst tied to the stock’s weakness.

Previously disclosed H1 figures showed EPS of $(2.43), materially worse than the $(1.08) consensus estimate, although sales of $2.959 million exceeded the $1.860 million expectation. After the release, Wedbush cut its target price to $118 from $160 while keeping a neutral rating, and Truist also lowered its target. Abivax S.A.’s lead asset, obefazimod, remains in Phase 3 development for ulcerative colitis, leaving investor focus on trial, filing, and commercialization progress.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment